Pantoprazole Inpharmatis (Pantoprazole)

Pantoprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. This inhibition stops the final step of gastric acid production, leading to a sustained increase in gastric pH and allowing acid‑related lesions to heal.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, severity, and renal or hepatic function. Standard dosing regimens exist, but the prescriber tailors therapy to each individual case.

Safety data for pantoprazole during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Pantoprazole shares the same mechanism of action as other proton pump inhibitors such as omeprazole or esomeprazole, but it is formulated for intravenous administration, offering rapid and reliable acid suppression in patients who cannot take oral medications. Its pharmacokinetic profile provides consistent plasma concentrations with a lower potential for drug‑drug interactions compared with some oral PPIs.

The product should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Once reconstituted, it must be used within the time frame specified in the product label and kept under aseptic conditions.

Pantoprazole Inpharmatis is given by intravenous infusion. The solution is added to a compatible diluent and administered over a period defined by the prescriber, typically 15–30 minutes, ensuring aseptic technique and proper line flushing before and after the infusion.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhoea, significant hypomagnesemia, liver enzyme elevations, and rare skin disorders like Stevens‑Johnson syndrome. Patients should be monitored for any signs of these conditions, and therapy should be discontinued if they occur.

Patients with known hypersensitivity to pantoprazole or any component of the formulation should avoid its use. Caution is also advised for individuals with severe hepatic impairment, those receiving certain interacting drugs (e.g., clopidogrel, atazanavir, high‑dose methotrexate), and patients with a history of severe allergic reactions to proton pump inhibitors.